GlassScriptPhysician profile
Oliver L Ong
NPI 1811951734
$14,131.93
in general payments reported to CMS, 2019-2025
57 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $1,299 · 2021: $1,564 · 2022: $2,005 · 2023: $2,391 · 2024: $2,398 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,084 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,084.06 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,540.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,448.25 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,347.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $906.51 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $713.49 | 2019-2025 | |
| Dexcom, INC. | $616.18 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $533.68 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $527.19 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $444.09 | 2022-2025 | |
| Abbvie INC. | $413.09 | 2019-2025 | |
| Medtronic, INC. | $386.71 | 2021-2025 | Minimed 780g |
| Mannkind Corporation | $368.11 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $327.37 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $311.30 | 2019-2023 | Verquvo |
| Radius Health, INC. | $285.07 | 2020-2024 | Tymlos |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $221.16 | 2024-2025 | Tlando |
| Horizon Therapeutics Plc | $218.77 | 2019-2023 | Tepezza |
| Insulet Corporation | $197.15 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $158.93 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $158.42 | 2024-2025 | |
| Valeritas, INC. | $141.69 | 2019 | |
| Corcept Therapeutics | $130.83 | 2019-2025 | Korlym |
| Becton, Dickinson and Company | $116.19 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $114.88 | 2024-2025 | Yorvipath |
| Lexicon Pharmaceuticals, INC. | $109.35 | 2024 | |
| Ibsa Pharma INC. | $109.25 | 2019-2022 | |
| Amphastar Pharmaceuticals, INC. | $95.12 | 2024-2025 | |
| Amarin Pharma, INC. | $92.42 | 2019-2020 | |
| Antares Pharma, INC. | $88.69 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Cequr Corporation | $85.58 | 2023 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $82.57 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $69.80 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $65.21 | 2023-2025 | |
| Amryt Pharma Holdings LTD | $56.47 | 2021-2023 | Mycapssa |
| Nestle Healthcare Nutrition INC. | $47.28 | 2021 | |
| Embecta Corp. | $46.73 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $43.88 | 2025 | Twiist |
| Pfizer INC. | $42.64 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $41.20 | 2019-2023 | |
| Vistapharm, INC. | $39.70 | 2021 | |
| Globus Medical, INC. | $37.14 | 2025 | Senza |
| Medtronic Minimed, INC. | $36.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.68 | 2019 | |
| Ionis Pharmaceuticals, INC. | $34.33 | 2025 | Tryngolza |
| Averitas Pharma INC. | $31.91 | 2024 | Qutenza |
| Acerus Pharmaceuticals Corporation | $25.71 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $23.35 | 2025 | Imcivree |
| Halozyme INC | $23.00 | 2023 | |
| Recordati_rare_diseases_inc. | $18.95 | 2022 | |
| Eusa Pharma (US) LLC | $18.95 | 2022 | |
| Vertiflex, INC. | $18.14 | 2019 | |
| Shire North American Group INC | $16.56 | 2019 | |
| Tolmar, INC. | $15.87 | 2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $15.24 | 2025 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $14.41 | 2020 | |
| Glaxosmithkline, LLC. | $12.39 | 2020 | |
| Allergan, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.